Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05271630 · ClinicalTrials.gov registry record
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
A clinical trial of Multiple Myeloma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- 69
- Enrollment target
- 1
- Study location
NCT05271630 is a study of Multiple Myeloma that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 69 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05271630, a study of Multiple Myeloma, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
Conditions Studied
Interventions
- OTHER Autologous Stem Cell Transplant
- DRUG Immunomodulatory Agent
- DRUG Proteasome Inhibitor
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05271630
The ClinicalTrials.gov registry entry for NCT05271630 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Autologous Stem Cell Transplant is the first listed.
NCT05271630 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05271630 about?
NCT05271630 is a clinical study titled "Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant". The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
What is the current status of trial NCT05271630?
This trial is currently active not recruiting. The enrollment target is 69 participants. The study started on 2022-04-20. Estimated completion is 2026-12.
What conditions does trial NCT05271630 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05271630?
The interventions under investigation include: Autologous Stem Cell Transplant (OTHER), Immunomodulatory Agent (DRUG), Proteasome Inhibitor (DRUG).
Who is sponsoring clinical trial NCT05271630?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05271630 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.